You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Optimized lactoferrin for treatment of intracerebral hemorrhage
SBC: Pharmareview Corporation Topic: NINDSDESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Ovarian cancer using novel nanoparticle formulations
SBC: KIROMIC BIOPHARMA INC Topic: 102DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New heterocyclic inhibitors of filoviruses
SBC: MICROBIOTIX, INC. Topic: HDESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New small molecule inhibitors of arenaviruses
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a Peptide Microchip System
SBC: ATACTIC TECHNOLOGIES, INC. Topic: N/ADESCRIPTION (provided by applicant): The purpose of this proposal is to develop a protein assay technology that will parallel the newly developing oligonucleotide microarray techniques. We will develop a peptide system capable of performing high throughput real time measurements in parallel on a microfluidic chip. We will develop the chemistry to prepare these chips in Phase I and develop the s ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Ultra-micro oxygen sensor development
SBC: Biocurrents Research, Inc. Topic: N/ADESCRIPTION (provided by applicant): The overall aim of this STTR proposal is to take an innovative, successful; laboratory based technology and transfer it to the commercial sector. Specifically, we wish to establish the capabilities within the Company to manufacture reliable, robust and inexpensive ultra-micro oxygen sensors suitable for electrochemical applications related to cellular metabolis ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Novel pharmacotherapies for treatment of ADHD
SBC: Biostream Therapeutics, Inc. Topic: N/ADESCRIPTION (provided by applicant): Attention-deficit hyperactivity disorder (ADHD) is a common neuropsychiatric condition characterized by hyperactivity, inattention and impulsivity, typically in school-aged boys. Psychostimulants, including methylphenidate and amphetamines, are commonly used to alleviate symptoms of ADHD. However, these medications are typically associated with undesirable sid ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Development of a peptide array synthesis system
SBC: Boston Array Technologies, Inc. Topic: N/ADESCRIPTION (provided by applicant): The overall goal of phase I and II of this proposal is to develop microarray-based methods for high throughput profiling of proteins. This will be done in two different ways, one based on arrays of 100s of thousands of distinct peptides on 1 cm2 chips that can be used to fingerprint proteins, the other based on thousands or tens of thousands of antibodies again ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Method for Discovering Novel Transcriptional Regulators
SBC: CROSSLINK GENETICS CORPORATION Topic: N/ADESCRIPTION (provided by applicant): Regulation of gene expression by transcription factors is one of the most fundamental biological processes. The pharmaceutical manipulation of this process would open doors toward new approaches to treatment of cancer and other major diseases. We aim to develop a novel, comprehensive technology for manipulation of gene expression based on synthetic analogu ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health